European journal of neurology : the official journal of the European Federation of Neurological Societies
-
Randomized Controlled Trial
Efficacy of Galcanezumab in Patients with Episodic Migraine and a History of Preventive Treatment Failure: Results from Two Global Randomized Clinical Trials.
The efficacy of galcanezumab, a monoclonal antibody for migraine prevention, has been demonstrated in two pivotal trials in patients with episodic migraine. ⋯ In patients with episodic migraine treated with galcanezumab, those with ≥1 or ≥2 prior preventive failures had significantly larger improvements, versus placebo, in efficacy outcomes. Similar results were observed in patients with no prior failure, with a larger placebo response.
-
The pathophysiology of Parkinson's disease (PD) remains unclear. Voxel-based morphometry (VBM) detects local structural differences in brain tissue such as grey matter volume (GMV) between groups, which is helpful in understanding the pathophysiology of PD. Published VBM studies of GMV changes in PD have shown inconsistent results. Therefore, a voxel-wise meta-analysis of VBM studies was conducted to detect consistent GMV changes in PD. ⋯ Parkinson's disease patients have GMV reductions in a number of brain regions involved in specific networks. These findings provide morphological evidence for the pathophysiology of PD.